ANTIBODIES DIRECTED TO CD127 Russian patent published in 2020 - IPC C07K16/28 A61K39/395 

FIELD: pharmaceuticals.

SUBSTANCE: group of inventions refers to an antibody or its antigen-binding fragment which specifically binds CD127 and use of said antibody or its antigen-binding fragment. Antibody or its antigen-binding fragment contains a VH-chain containing the following amino acid sequences VHCDR1 SEQ ID No: 10, VHCDR2 SEQ ID No: 12, VHCDR3 SEQ ID No: 14 or SEQ ID No: 48; and a VL-chain comprising the following amino acid sequences VLCDR1 SEQ ID No: 16 or SEQ ID No: 50; VLCDR2 SEQ ID No: 18 or SEQ ID No: 52; VLCDR3 SEQ ID No: 20. Also disclosed are a macromolecule which is a conjugate and containing said antibody or its antigen-binding fragment; nucleic acid molecule, coding antibody or its antigen-binding fragment. Disclosed also is a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof, or said macromolecule, or said nucleic acid molecule. Said antibody or its antigen-binding fragment, macromolecule, nucleic acid molecule, pharmaceutical composition can be used for treating condition, which can be improved or prevented by IL7-induced signaling IL7-R antagonisation. What is also presented is a method of treating, a method for producing the antibody and a method for selecting the antibody.

EFFECT: disclosed antibody or its antigen-binding fragment is highly effective.

35 cl, 12 tbl, 21 ex, 28 dwg